New CSO key to driving disruptive technologies development

Dr Daniel Turner has been appointed as Chief Scientific Officer by Enhanc3D Genomics, developers of disruptive technologies aimed at unlocking the 3D spatial genome for target and biomarker discovery.

Dan’s deep expertise in genomics technology development and commercialisation will be key to driving development of the company’s scientific strategy, extending its GenLink3D™ technology into next-generation versions requiring only minimal, or even single cell-level, inputs. He will also build commercial and academic partnerships for the development of candidate therapeutic targets identified from the platform. His appointment follows that of Hazel Jones as Chief Operating Officer in November 2023.

With over 20 years of senior leadership experience in genetics, molecular biology and sequencing research, he joins from Oxford Nanopore Technologies, where he held roles including Senior Vice President, Vice President and Senior Director of Applications. For over more than 13 years, he established strategic collaborations and was project lead on applications technology. Prior to this he was head of Sequencing Technology Development at the Wellcome Trust Sanger Institute, which followed postdoctoral roles at Wellcome Sanger and at Weill Cornell Medical College. He holds a degree in Biochemistry from the University of Oxford and completed an MSc and PhD in Genetics at the University of Manchester Institute of Science and Technology.

Dr Hazel Jones, COO and interim Chief Executive Officer at Enhanc3D Genomics, said: “Dan joins us at an exciting stage in the Company’s development as we begin to steer towards commercialisation. His expertise and guidance, based on his vast experience in successfully leading multidisciplinary teams in genomics and technology development, will be pivotal to the delivery of our strategic growth initiatives. I look forward to working alongside Dan as he joins the team.”

Dr Dan Turner commented: “Enhanc3D Genomics has an exceptional reputation in the field of 3D genomics and I’m delighted to take this opportunity to help drive the development of its technology further. There is extensive scope to expand the technology into other disease areas as the Company continues to build its database of candidate therapeutic targets.”

More information online